| Literature DB >> 32089804 |
Mostafa Hemamy1, Motahar Heidari-Beni2, Gholamreza Askari1, Mojgan Karahmadi3, Mohammadreza Maracy4.
Abstract
BACKGROUND: Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by the three main symptom domains including inattention, hyperactivity, and impulsivity. Recent findings suggested that nutrients might play an important role in the pathology of ADHD. The present study aimed to examine the effects of Vitamin D and magnesium supplementation on behavior problems in children with ADHD.Entities:
Keywords: Attention-deficit disorder with hyperactivity; Vitamin D; magnesium; randomized clinical trial
Year: 2020 PMID: 32089804 PMCID: PMC7011463 DOI: 10.4103/ijpvm.IJPVM_546_17
Source DB: PubMed Journal: Int J Prev Med ISSN: 2008-7802
Figure 1Participants’ flow diagram
General characteristics of the study participantsa
| Intervention ( | Control ( | ||
|---|---|---|---|
| Age (years) | 9.06±1.76 | 9.15±1.46 | 0.80 |
| Weight (kg) | 31.33±9.93 | 31.17±8.82 | 0.96 |
| Height (cm) | 129.46±11.12 | 129.34±9.48 | 0.87 |
| BMI (kg/m²), | |||
| Underweight | 3 (9.10) | 1 (3.00) | 0.66 |
| Normal weight | 17 (51.50) | 21 (63.60) | |
| Overweight | 8 (24.20) | 7 (21.20) | |
| Obese | 5 (15.20) | 4 (12.10) | |
| Sex, | |||
| Boy | 23 (69.7) | 23 (69.7) | 0.99 |
| Girl | 10 (30.3) | 10 (30.3) | |
| Ritalin dose (mg/kg) | 31.33±9.93 | 31.21±8.81 | 0.93 |
aData are presented as means±SD other than those specified, bFor comparison of numerical values Mann–Whitney test, and for qualitative values, Fisher’s exact test has been used. BMI=Body mass index, SD=Standard deviation
The effect of Vitamin D and magnesium supplementation in children with attention-deficit hyperactivity disorder based on Conners̕ parent rating scalea
| Scales | Intervention ( | Control ( | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 8th week | Changeb | Baseline | 8th week | Changeb | ||||
| Conduct problems score | 16.91±1.78 | 13.61±1.45 | −3.30±0.51 | 17.24±1.62 | 17.48±1.56 | 0.24±0.16 | 0.69 | 0.05 | 0.001 |
| Social problems score | 10.24±1.08 | 8.03±0.96 | −2.21±0.51 | 10.42±1.03 | 10.61±1.00 | 0.18±0.19 | 0.86 | 0.07 | 0.001 |
| Psychosomatic problems score | 8.79±0.90 | 8.55±0.84 | −0.24±0.16 | 9.00±0.88 | 9.03±0.88 | 0.03±0.06 | 0.81 | 0.69 | 0.20 |
| Anxiety-shy score | 8.24±0.65 | 6.82±0.55 | −1.42±0.25 | 8.06±0.61 | 8.09±0.60 | 0.03±0.06 | 0.86 | 0.09 | 0.001 |
aReported values are means±SEM, bCalculated by subsidizing values at 8th week from values at baseline, cComparison of values at baseline between the two groups using Mann–Whitney test, dComparison of values at 8th week between the two groups using Mann–Whitney test, eComparison of values changes between the two groups using Mann–Whitney test, c,d,eThe P=0.05 considered as significance level. SEM=Standard error of mean
Figure 2Serum 25-hydroxy-Vitamin D levels of participants at study baseline and end of trial. P values obtained from Mann–Whitney test. P value for comparison of changes between the two groups was 0.001
Figure 3Serum magnesium levels of participants at study baseline and end of trial. P values obtained from Mann–Whitney test. P value for comparison of changes between the two groups was 0.001